Tested Applications
| Positive WB detected in | human brain tissue, NCI-H1299 cells, A549 cells |
| Positive IHC detected in | human spleen tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | A549 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
20564-1-AP targets PAFAH1B3 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29kDa |
| Calculated Molecular Weight | 26 kDa |
| Observed Molecular Weight | 26-29 kDa |
| GenBank Accession Number | NM_002573 |
| Gene Symbol | PAFAH1B3 |
| Gene ID (NCBI) | 5050 |
| RRID | AB_10693534 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q15102 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
PAFAH1B3, also named as PAFAHG, belongs to the 'GDSL' lipolytic enzyme family and Platelet-activating factor acetylhydrolase IB beta/gamma subunits subfamily. It inactivates paf by removing the acetyl group at the sn-2 position. This is a catalytic subunit. PAFAH1B3 plays an important role during the development of brain. The antibody is specific to PAFAH1B3.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for PAFAH1B3 antibody 20564-1-AP | Download protocol |
| IHC protocol for PAFAH1B3 antibody 20564-1-AP | Download protocol |
| WB protocol for PAFAH1B3 antibody 20564-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The PAFAH1B3 Polyclonal antibody (Cat# 20564-1-AP) has 6 total citations. These appear in Biochemical Pharmacology, International Journal of Molecular Sciences, Discovery Oncology (two papers), OncoTargets and Therapy, and Communications Chemistry. The associated research fields span gastric cancer progression, hepatocellular carcinoma (HCC) and EMT, tumor stemness and T-cell exhaustion immune microenvironment, hypopharyngeal squamous cell carcinoma prognosis, and lung cancer proteomics/drug target identification.
| Species | Application | Title |
|---|---|---|
Biochem Pharmacol PAFAH1B3 promotes gastric cancer progression by enhancing E2F8-mediated transcriptional activation of VEGFA expression. | ||
Int J Mol Sci PAFAH1B3 Exists in Linear Chromosomal and Extrachromosomal Circular DNA and Promotes HCC Progression via EMT.
| ||
Discov Oncol Increased PAFAH1B3 was associated with poor prognosis and T-cell exhaustion microenvironment in hepatocellular carcinoma | ||
Discov Oncol Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma | ||
Onco Targets Ther Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.
| ||
Commun Chem ThermoTargetMiner as a proteome integral solubility alteration target database for prospective drugs against lung cancer. |









